Respiratory syncytial virus after the SARS-CoV-2 pandemic — what next?

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection. It is a large contributor to infant hospitalization and also has a substantial burden in older adults ( ≥ 65 years). The non-pharmaceutical interventions that were introduced to limit the spread of SARS-CoV-2 have had a marked effect on the transmission of RSV, particularly its seasonality. Here, we consider the implications of these changes to RSV transmission for future prevention strategies.